BPH Treatment Options in Irvine: Medication, PAE, and Surgery

Editorially updated July 20, 2026. Prepared by SoCal Interventional using the clinical sources listed below. Treatment selection requires individual medical evaluation.

BPH treatment is not a simple choice between medication and surgery. Options differ in how they work, which prostates they suit, how much urinary improvement they may provide, how quickly they work, and their possible effects on ejaculation, continence, anesthesia exposure, and retreatment.

Patients comparing BPH treatment options in Irvine should first confirm that benign prostate enlargement is responsible for their symptoms. Urgency, nighttime urination, weak stream, and incomplete emptying can have overlapping prostate, bladder, medication, metabolic, or neurologic causes.

Observation and symptom monitoring

When symptoms are mild and complications are absent, observation may be appropriate. Fluid timing, caffeine or alcohol reduction, constipation management, and medication review may help some patients. Monitoring matters because bladder emptying and symptom burden can worsen over time.

Medication

Common medication categories include alpha blockers, 5-alpha-reductase inhibitors, tadalafil, and selected combinations. Alpha blockers may improve symptoms relatively quickly but can affect blood pressure or ejaculation. Drugs that shrink the prostate generally take longer and may cause sexual side effects. The best choice depends on prostate size, other conditions, medicines, and patient priorities.

A randomized comparison of PAE with combined medical therapy in a defined group of patients with larger prostates and persistent symptoms reported greater symptom improvement after PAE through the study period. Those findings do not mean every newly diagnosed patient should skip medication; the population and eligibility criteria matter.

Prostate artery embolization

PAE is performed through a small arterial puncture. An interventional radiologist guides a catheter to selected prostate arteries and delivers microscopic particles to reduce blood flow. Prostate tissue may shrink gradually and urinary symptoms may improve over weeks to months.

Potential advantages include avoidance of transurethral tissue removal and outpatient care in many cases. Important limitations include variable response, a technically demanding procedure, radiation and contrast exposure, and the possibility of later medication, repeat embolization, or surgery.

Transurethral and surgical procedures

Options can include TURP, HoLEP or other laser procedures, aquablation, water-vapor therapy, prostatic urethral lift, and additional techniques. Eligibility depends on prostate size and anatomy, obstruction severity, retention, bladder function, bleeding risk, available expertise, and individual goals.

Tissue-removing procedures often provide stronger or faster improvement in urinary flow than PAE. In a five-year randomized PAE-versus-TURP trial, both groups improved, but TURP was superior for several patient-reported and objective urinary outcomes. Surgical options can also involve anesthesia, catheterization, bleeding, incontinence, urethral complications, and ejaculatory changes; risk varies by procedure and patient.

How sexual priorities affect the choice

Some patients prioritize preservation of ejaculation or erectile function. PAE avoids cutting or heating tissue inside the urethra, and many studies report relatively low sexual side-effect rates. However, a study specifically assessing ejaculation after PAE documented new ejaculatory dysfunction in some patients. Sexual-function preservation should be discussed as a probability, not a guarantee.

Questions that help compare options

• What is causing my symptoms, and is there measurable obstruction?
• How large is the prostate and which anatomical features matter?
• How much and how quickly might each option improve symptoms and flow?
• What are the anesthesia, catheter, bleeding, sexual, continence, and retreatment tradeoffs?
• Could delayed treatment harm my bladder or kidneys?
• Which treatment does the clinician perform most often, and why is it recommended for me?

A coordinated decision

The AUA guideline supports a shared decision based on symptom burden, anatomy, risks, and goals. Some patients benefit from both urologic and interventional-radiology opinions. Read PAE versus TURP for a more focused comparison.

Sources

• NIDDK: Enlarged Prostate (BPH)
• AUA BPH guideline
• PARTEM randomized trial: PAE versus combined medication
• Five-year randomized PAE versus TURP trial
• Ejaculatory function after PAE
• SoCal Interventional medical editorial policy

To request an evaluation in Irvine, call (310) 929-0026. The appropriate option cannot be selected from prostate size or symptoms alone.